NeoGenomics, Inc. (NASDAQ:NEO) General Counsel Alicia C. Olivo Sells 2,669 Shares of Stock

NeoGenomics, Inc. (NASDAQ:NEO) General Counsel Alicia C. Olivo sold 2,669 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $18.39, for a total value of $49,082.91. Following the transaction, the general counsel now owns 37,140 shares of the company’s stock, valued at $683,004.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

NeoGenomics Trading Up 0.5 %

Shares of NASDAQ:NEO opened at $19.51 on Tuesday. The stock has a market capitalization of $2.49 billion, a price-to-earnings ratio of -25.34 and a beta of 1.23. The company has a debt-to-equity ratio of 0.57, a quick ratio of 6.06 and a current ratio of 6.32. The stock’s 50-day simple moving average is $13.96 and its two-hundred day simple moving average is $15.45. NeoGenomics, Inc. has a 52-week low of $8.70 and a 52-week high of $20.54.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NEO. BluePath Capital Management LLC purchased a new position in NeoGenomics in the third quarter worth about $30,000. Coppell Advisory Solutions LLC purchased a new position in shares of NeoGenomics during the 2nd quarter valued at about $42,000. Captrust Financial Advisors lifted its position in shares of NeoGenomics by 17.1% during the 2nd quarter. Captrust Financial Advisors now owns 5,780 shares of the medical research company’s stock valued at $47,000 after buying an additional 844 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of NeoGenomics by 165.6% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,312 shares of the medical research company’s stock valued at $58,000 after buying an additional 2,065 shares in the last quarter. Finally, HighMark Wealth Management LLC lifted its position in shares of NeoGenomics by 41.7% during the 2nd quarter. HighMark Wealth Management LLC now owns 4,250 shares of the medical research company’s stock valued at $68,000 after buying an additional 1,250 shares in the last quarter. 91.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on NEO. Morgan Stanley raised their price target on NeoGenomics from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Wednesday, November 8th. Needham & Company LLC restated a “buy” rating and set a $21.00 price target on shares of NeoGenomics in a report on Tuesday, November 7th. Piper Sandler reduced their price target on NeoGenomics from $23.00 to $18.00 and set an “overweight” rating for the company in a report on Monday, October 16th. William Blair restated an “outperform” rating on shares of NeoGenomics in a report on Monday, August 28th. Finally, Stephens upgraded NeoGenomics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $16.00 to $18.00 in a report on Monday, August 21st. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, NeoGenomics has an average rating of “Moderate Buy” and an average target price of $19.00.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.